A phase III, multicentre, randomised, double-blind, active-controlled, parallel-group trial comparing safety and efficacy of HD203, with innovator etanercept, in combination with methotrexate, in patients with rheumatoid arthritis: the HERA study
- Ann. Rheum. Dis., Published Online First 23 February 2016 | doi:10.1136/annrheumdis-2015-207613